SNIPR Biome Receives CARB-X Funding to Test...
CMN Briefs
Apr. 22, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Bayer
Main (gene editing) focus: Next-generation in vivo delivered gene-editing therapies
Company stage: Commercial
Diseases (gene editing): Genetic diseases of the liver, haemophilia, ophthalmology and autoimmune diseases
Genome editing tool: CRISPR-Cas9, Cas14 and Casɸ
Funding stage: Public (XETRA:BAYN.DE)
Location: Berlin, Germany
Website: https://www.bayer.com/en/pharma/development-pipeline
Pipeline: https://www.bayer.com/en/pharmaceuticals
Gene editing partnerships: Mammoth Biosciences, Casebia Therapeutics
Bayer is a big pharma company with worldwide operations. The company is engaged in the gene-editing field by its joint venture firm, Casebia Therapeutics, which it launched together with CRISPR Therapeutics. The company also announced a collaboration with Mammoth Biosciences, where the two companies will utilise Mammoth's ultra-small Cas enzymes, Cas14 and Casɸ, for in vivo gene editing of multiple disease targets.
